Aligos Therapeutics (ALGS) Expected to Post Quarterly Earnings on Wednesday

Aligos Therapeutics (NASDAQ:ALGS) is projected to announce its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Aligos Therapeutics to post earnings of ($1.41) per share and revenue of $24.6750 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 9:30 AM ET.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The company had revenue of $2.83 million for the quarter, compared to the consensus estimate of $0.25 million. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. On average, analysts expect Aligos Therapeutics to post $-7 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Aligos Therapeutics Trading Up 4.2%

Shares of NASDAQ ALGS opened at $4.25 on Wednesday. Aligos Therapeutics has a 1 year low of $3.98 and a 1 year high of $13.69. The firm’s 50-day moving average is $5.48 and its 200-day moving average is $6.64. The firm has a market capitalization of $26.31 million, a PE ratio of -0.49 and a beta of 2.26.

Analyst Ratings Changes

Several equities analysts recently weighed in on ALGS shares. Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, May 17th. Lake Street Capital initiated coverage on shares of Aligos Therapeutics in a report on Thursday, May 28th. They set a “buy” rating and a $45.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aligos Therapeutics in a report on Friday, May 29th. Finally, Weiss Ratings upgraded shares of Aligos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.50.

Hedge Funds Weigh In On Aligos Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in shares of Aligos Therapeutics by 21.3% during the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after buying an additional 5,978 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Aligos Therapeutics in the 3rd quarter valued at approximately $99,000. LPL Financial LLC boosted its stake in Aligos Therapeutics by 19.7% during the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock worth $615,000 after acquiring an additional 10,880 shares during the last quarter. HRT Financial LP bought a new position in Aligos Therapeutics during the 4th quarter worth approximately $106,000. Finally, Squarepoint Ops LLC boosted its stake in Aligos Therapeutics by 64.0% during the 3rd quarter. Squarepoint Ops LLC now owns 30,493 shares of the company’s stock worth $299,000 after acquiring an additional 11,904 shares during the last quarter. Institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.